Krassimir Koynov
A5074747094- Fibroblast Growth Factor Research
- Medical Imaging and Pathology Studies
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Telomeres, Telomerase, and Senescence
- Nanoplatforms for cancer theranostics
- Inflammatory Biomarkers in Disease Prognosis
- Radiopharmaceutical Chemistry and Applications
- BRCA gene mutations in cancer
- Drug Transport and Resistance Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal Tumor Research and Treatment
- Chemokine receptors and signaling
National Institute of Emergency Medicine "Pirogov"
2018-2020
Hospital Sírio-Libanês
2012
Universidade de São Paulo
2012
Instituto do Câncer do Estado de São Paulo
2012
Jena University Hospital
2012
Queen Giovanna Hospital
2010
Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all three VEGF receptors. HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine oxaliplatin (FOLFOX/CAPOX) or without cediranib patients previously untreated metastatic colorectal cancer (mCRC).Eligible were...
The aim of this multicentric retrospective study is to evaluate the predictive and prognostic performance neutrophil lymphocyte ratio (NLR), platelet-lymphocyte (PLR) their dynamics in patients with non-small cell lung cancer (NSCLC) treated pembrolizumab as a second line. Patients metastatic NSCLC (n = 119), whose tumors expressed programmed death-ligand 1 (PD-L1) ≥ 1%, were retrospectively analyzed between Apr 2017 2019. All received platinum-containing chemotherapy first line treatment....
The randomised phase III TURANDOT trial compared first-line bevacizumab–paclitaxel (BEV–PAC) vs bevacizumab–capecitabine (BEV–CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). interim analysis revealed no difference overall survival (OS; primary end point) between treatment arms; however, progression-free (PFS) and objective response rate were significantly superior with BEV–PAC. We sought to identify patient populations that may be most appropriately treated one or...
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion this study, activity, safety, tolerability, effects on quality life combination with gemcitabine was examined 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract 13 bladder patients. All patients received 135 mg/m2 day one 1,250 days eight. The median...
This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor FGFR1-3, in patients with solid tumors harboring a functional FGFR1-3 fusion.
8601 Background: Despite recent approvals for the first-line (1L) treatment of advanced non-small-cell lung cancer (NSCLC), long-term prognosis remains poor with a 5-year survival rate 28% and limited options exist in patients (pts) refractory or resistant to immune checkpoint inhibitors (ICI). THIO (6-thio-2’-deoxyguanosine) is small molecule, first-in-class direct telomere-targeting agent that selectively targets telomerase positive (TERT+) cells. It incorporated de novo synthesized...
<p>Supplementary Figure S2. Progression-free survival.</p>
<p>Supplementary methods</p>
<p>Supplementary Figure S1. Study CONSORT diagram.</p>